Alpha Mannosidosis Market By Indication Type (Type I, Type II, Type III), By Treatment (Bone Marrow Treatment, Enzyme Replacement Treatment) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Aplha mannosidosis is a rare genetic disorder belonging to a group of diseases known as lysosomal storage disorders. Aplha mannosidosis occurs in 1 in every 500,000 people in the general population and is characterized by a deficiency of the enzyme alpha-D-mannosidase. The symptoms, progression and severity of alpha-mannosidosis vary widely from one person to another, including between siblings who share the same mutation.

The report titled “Global Alpha Mannosidosis Market- Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the alpha mannosidosis market along with the market size and estimates for the duration 2017 to 2025. The research study covers in-depth analysis of market segments based on Indication type, treatment and different geographical region.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global alpha mannosidosis market, attractive investment proposition and market positioning of key manufacturers sections.

Geographically, the global alpha mannosidosis market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of MEA

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global alpha mannosidosis market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global alpha mannosidosis market. This report concludes with company profiles section that highlights major information about the key players engaged in global alpha mannosidosis market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report. 

Thus, the research study provides a holistic view of the global alpha mannosidosis market, offering market size and estimates for the period from 2017 to 2025, keeping in mind the above-mentioned factors.

Alpha Mannosidosis Market

For the purpose of this study, the global alpha mannosidosis market is categorized as follows:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Alpha Mannosidosis Market

For the purpose of this study, the global alpha mannosidosis market is segmented into regional markets such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America held the largest share in the alpha mannosidosis market due increased clinical trials in the regions. After the Orphan Drugs Act passed in the U.S., the development and approval of drugs for orphan diseases has escalated. As a result, it has emerged as the biggest benefit for the pharmaceutical companies to launch orphan drugs in a fast track basis. The ERT drug for alpha mannosidosis named Lamazym has also been given the orphan drug status across Europe and the U.S. Asia Pacific is projected to grow at a fastest growth rate during the forecast period. The growth will be attributed to the rising awareness about the disease in the developing countries. Government of Australia has implemented a national plan for helping patients with rare diseases to reduce the mortality rate due to these diseases. The plan aims to raise awareness about the burden of rare diseases among patients, its impact on social life, and healthcare professionals.

Choose License Type
Published Date:  Oct 2018
Category:  Pharmaceuticals
Report ID:   58561
Report Format:   PDF
Pages:   120
Rating:    4.3 (50)
Connect With Us
24/7 Research Support